AVADEL PHARMACEUTICALS PLC — Director's Dealing 2019

Nov 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2019-11-15

Reporting Person: Glass Geoffrey Michael (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-15	ADSs	P	5000	$4.99	Acquired	32900	Direct
2019-11-18	ADSs	P	15000	$4.99	Acquired	47900	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$2.03	2029-08-07	ADSs (60000)	60000	Direct

Footnotes

F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

F2: Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.

F3: The price reported in Column 4 is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $4.95 to $5.04, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs purchased at each separate price within the ranges set forth in this footnote (3).

F4: Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date.